In addition, in the third group of patients with positive ERα expression, even though the expression of ERβ was high, the increase in the risks of overall mortality and cancer recurrence was much lower than that in the first group with combined high ERβ + negative ERα expression (3 and 22% lower, respectively: Supplementary Table 1, multivariate analysis). The gene discussed is ESR2; the disease is cancer.